Education
About Us
Working with TipRanks
Follow Us
Processa Pharmaceuticals, Inc. (PCSA)
:PCSA
RESEARCH TOOLSreports
Total Valuation
Processa Pharmaceuticals has a market cap or net worth of $5.14M. The enterprise value is $4.73M.
Market Cap$5.14M
Enterprise Value$4.73M
Share Statistics
Processa Pharmaceuticals has 26,194,357 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,194,357
Owned by Insiders5.86%
Owned by Institutions0.92%
Financial Efficiency
Processa Pharmaceuticals’s return on equity (ROE) is -6.99 and return on invested capital (ROIC) is -713.74%.
Return on Equity (ROE)-6.99
Return on Assets (ROA)-3.67
Return on Invested Capital (ROIC)-713.74%
Return on Capital Employed (ROCE)-7.10
Revenue Per Employee0.00
Profits Per Employee-1.19M
Employee Count10
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Processa Pharmaceuticals is -0.23. Processa Pharmaceuticals’s PEG ratio is -0.01.
PE Ratio-0.23
PS Ratio0.00
PB Ratio0.78
Price to Fair Value1.59
Price to FCF-0.63
Price to Operating Cash Flow-0.23
PEG Ratio-0.01
Income Statement
In the last 12 months, Processa Pharmaceuticals had revenue of 0.00 and earned -11.85M in profits. Earnings per share was -3.62.
Revenue0.00
Gross Profit0.00
Operating Income-12.05M
Pretax Income-11.85M
Net Income-11.85M
EBITDA-11.85M
Earnings Per Share (EPS)-3.62
Cash Flow
In the last 12 months, operating cash flow was -11.93M and capital expenditures -3.24K, giving a free cash flow of -11.93M billion.
Operating Cash Flow-11.93M
Free Cash Flow-11.93M
Free Cash Flow per Share-0.46
Dividends & Yields
Processa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.08
52-Week Price Change-90.43%
50-Day Moving Average0.26
200-Day Moving Average0.73
Relative Strength Index (RSI)40.28
Average Volume (3m)31.82M
Important Dates
Processa Pharmaceuticals upcoming earnings date is Aug 7, 2025, After Close (Confirmed).
Last Earnings DateMar 27, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Processa Pharmaceuticals as a current ratio of 1.22, with Debt / Equity ratio of 1.41%
Current Ratio1.22
Quick Ratio1.22
Debt to Market Cap0.03
Net Debt to EBITDA0.09
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Processa Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Processa Pharmaceuticals EV to EBITDA ratio is -0.13, with an EV/FCF ratio of -0.14.
EV to Sales0.00
EV to EBITDA-0.13
EV to Free Cash Flow-0.14
EV to Operating Cash Flow-0.14
Balance Sheet
Processa Pharmaceuticals has $2.90M in cash and marketable securities with $49.66K in debt, giving a net cash position of -$2.85M billion.
Cash & Marketable Securities$2.90M
Total Debt$49.66K
Net Cash-$2.85M
Net Cash Per Share-$0.11
Tangible Book Value Per Share$0.55
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Processa Pharmaceuticals is $6.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$6.00
Price Target Upside2900.00% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast56.26%